Ultra-Low BCR::ABL1 positivity by digital PCR does not improve post-transplant risk stratification beyond real-time PCR in Ph+ acute lymphoblastic leukemia post-transplant.
Saved in:
| Title: | Ultra-Low BCR::ABL1 positivity by digital PCR does not improve post-transplant risk stratification beyond real-time PCR in Ph+ acute lymphoblastic leukemia post-transplant. |
|---|---|
| Authors: | Luo Y; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Chen WM; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Zhao XS; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Chang YJ; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Zhao T; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Wu Y; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Cheng YF; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Mo XD; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Sun YQ; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Wang Y; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Xu LP; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Zhang XH; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Huang XJ; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China., Qin YZ; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China. qin2000@aliyun.com., Lv M; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China. drlvmeng@bjmu.edu.cn.; Clinical Trial Institution and Clinical Research Ward, Peking University People's Hospital, No. 11 Xizhimen South, Beijing, 100044, China. drlvmeng@bjmu.edu.cn. |
| Source: | Clinical and experimental medicine [Clin Exp Med] 2026 May 13; Vol. 26 (1). Date of Electronic Publication: 2026 May 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Electronic Cited Medium: Internet ISSN: 1591-9528 (Electronic) Linking ISSN: 15918890 NLM ISO Abbreviation: Clin Exp Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1591-9528 |
|---|---|
| DOI: | 10.1007/s10238-026-02172-w |
